Clover Health Investments (CLOV) Confirms SEC Investigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Clover Health (CLOV) Response to Short Seller 'Compelling' - BofA Securities
February 5, 2021 8:28 AM ESTBofA Securities analyst Kevin Fischbeck reiterated a Buy rating and $20.00 price target on Clover Health (NASDAQ: CLOV), saying the company's response to the short seller was "compelling."
For an analyst ratings summary and ratings history on Clover Health... More
Hindenburg Research Negative on Clover Health (CLOV), Calls Out SPAC King Chamath Palihapitiya
February 4, 2021 8:18 AM EST(Updated - February 4, 2021 8:20 AM EST)
Hindenburg Research issued a negative on Clover Health (NASDAQ: CLOV).
Hindenburg said SPAC King Chamath Palihapitiya misled investors about critical aspects of Clovers business in the run-up to the companys SPAC go-public transaction last... More
